Nicola Gallagher
- Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyBy Edward Kerwin, Jacques Hébert, Nicola Gallagher, Carmen Martin, Tim Overend, Vijay K.T. Alagappan, Yimeng Lu and Donald BanerjiEdward Kerwin*Clinical Research Institute of Southern Oregon, PC, Medford, ORJacques Hébert#Centre de Recherche Appliquée en Allergie de Québec, Québec, QC, CanadaNicola Gallagher¶Novartis Horsham Research Centre, Horsham, UKCarmen Martin¶Novartis Horsham Research Centre, Horsham, UKTim Overend¶Novartis Horsham Research Centre, Horsham, UKVijay K.T. Alagappan+Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAYimeng Lu+Novartis Pharmaceuticals Corporation, East Hanover, NJ, USADonald Banerji+Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyBy Eric D. Bateman, Gary T. Ferguson, Neil Barnes, Nicola Gallagher, Yulia Green, Michelle Henley and Donald BanerjiEric D. Bateman1Dept of Medicine, University of Cape Town, Cape Town, South AfricaGary T. Ferguson2Pulmonary Research Institute of Southeast Michigan, Livonia, MINeil Barnes3London Chest Hospital, Barts Health NHS Trust, LondonNicola Gallagher4Novartis Horsham Research Centre, Horsham, UKYulia Green4Novartis Horsham Research Centre, Horsham, UKMichelle Henley4Novartis Horsham Research Centre, Horsham, UKDonald Banerji5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Impact of teaching and awareness programme on doctors' knowledge of chest drain insertion siteBy Mithun Murthy, Joanna Gallagher and Nicola StevensonMithun MurthyRespiratory Medicine, Wirral University Teaching Hospitals, Upton, Wirral, United KingdomJoanna GallagherRespiratory Medicine, Wirral University Teaching Hospitals, Upton, Wirral, United KingdomNicola StevensonRespiratory Medicine, Wirral University Teaching Hospitals, Upton, Wirral, United Kingdom
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyBy Donald A. Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay K.T. Alagappan, Hungta Chen, Nicola Gallagher, Károly Kulich and Donald BanerjiDonald A. Mahler1Section of Pulmonary and Critical Care Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USAMarc Decramer2Division of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo3Dept of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaHeinrich Worth4Dept of Pneumology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVijay K.T. Alagappan5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAHungta Chen5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USANicola Gallagher6Novartis Horsham Research Centre, Horsham, UKKároly Kulich7Novartis Pharma AG, Basel, SwitzerlandDonald Banerji5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE studyBy Eric Bateman, Gary T. Ferguson, Neil Barnes, Nicola Gallagher, Yulia Green, Rachael Horton, Michelle Henley and Donald BanerjiEric Bateman1Department of Medicine, University of Cape Town, South AfricaGary T. Ferguson2Pulmonary Department, Pulmonary Research Institute of Southeast Michigan, Livonia, MI, United StatesNeil Barnes3London Chest Hospital, Barts Health NHS Trust, London, United KingdomNicola Gallagher4Respiratory Department, Novartis Horsham Resarch Centre, Horsham, United KingdomYulia Green4Respiratory Department, Novartis Horsham Resarch Centre, Horsham, United KingdomRachael Horton4Respiratory Department, Novartis Horsham Resarch Centre, Horsham, United KingdomMichelle Henley4Respiratory Department, Novartis Horsham Resarch Centre, Horsham, United KingdomDonald Banerji5Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE studyBy Donald A. Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay Alagappan, Hungta Chen, Karoly Kulich, Nicola Gallagher and Donald BanerjiDonald A. Mahler1Department of Medicine, Geisel School of Medicine, Dartmouth, Hanover, United StatesMarc Decramer2Department of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo3Department of Family and Community Medicine, University of Toronto, Toronto, CanadaHeinrich Worth4Departments of Pulmonology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesKaroly Kulich6Primary Care, Novartis Pharma AG, Basel, SwitzerlandNicola Gallagher7Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 provides superior peak lung function in patients with COPDBy Neil Barnes, Shu Hashimoto, Takahide Nagase, Hungta Chen, Nicola Gallagher, Peter D'Andrea, Vijay Alagappan and Donald BanerjiNeil Barnes1Department of Respiratory Medicine, London Chest Hospital, London, United KingdomShu Hashimoto2Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, JapanTakahide Nagase3Department of Respiratory Medicine, University of Tokyo, Tokyo, JapanHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesNicola Gallagher5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 improves symptom scores in patients with COPDBy Tobias Welte, Ronald Dahl, Hungta Chen, Nicola Gallagher, Peter D'Andrea, Vijay Alagappan and Donald BanerjiTobias Welte1Department of Respiratory Medicine, Hannover Medical School, Hannover, GermanyRonald Dahl2Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesNicola Gallagher4Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trialsBy Donald Banerji, Vijay Alagappan, Yulia Green, Nicola Gallagher, Angel FowlerTaylor, Peter D'Andrea and Hungta ChenDonald Banerji1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesYulia Green2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomNicola Gallagher2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomAngel FowlerTaylor1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPDBy Ronald Dahl, Nicola Gallagher, Yulia Green, Hannah Bryant, Hungta Chen, Peter D'Andrea, Vijay Alagappan and Donald BanerjiRonald Dahl1Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, DenmarkNicola Gallagher2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomYulia Green2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHannah Bryant2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME studyBy Jadwiga A. Wedzicha, Marc Decramer, Jørgen Vestbo, Nicola Gallagher, Han-Joo Kim, Danny McBryan and Donald BanerjiJadwiga A. Wedzicha1Department of Academic Respiratory Medicine, University College London, Royal Free Campus, London, United KingdomMarc Decramer2Respiratory Division, University Hospitals, University of Leuven, Leuven, BelgiumJørgen Vestbo3Respiratory Research Group, Manchester Academic Health Sciences Centre, Manchester, United KingdomNicola Gallagher4Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHan-Joo Kim5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDanny McBryan6Primary Care, Novartis Pharma AG, Basel, SwitzerlandDonald Banerji5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Development and validation of an innovative self-administered computerized (SAC) version of baseline/transition dyspnea index (BDI/TDI) for evaluating breathlessness in patients with COPD: The BLAZE studyBy Donald A. Mahler, Vanessa Brunel, Tracy White, Vijay Alagappan, Hungta Chen, Karoly Kulich, Nicola Gallagher and Donald BanerjiDonald A. Mahler1Department of Medicine, Geisel School of Medicine, Dartmouth, Hanover, United StatesVanessa Brunel2Linguistic Validation, MAPI Institute, Lyon, FranceTracy White3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesHungta Chen3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesKaroly Kulich4Primary Care, Novartis Pharma AG, Basel, SwitzerlandNicola Gallagher5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United States
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE studyBy Donald A Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay K. T. Alagappan, Hungta Chen, Nicola Gallagher, Károly Kulich and Donald BanerjiArticle | Published in 2013 in European Respiratory JournalDonald A Mahler*Section of Pulmonary & Critical Care Medicine; Geisel School of Medicine at Dartmouth; Hanover, NH, USAMarc Decramer#Division of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo¶Dept of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaHeinrich Worth+Depts of Pneumology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVijay K. T. Alagappan§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAHungta Chen§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USANicola GallagherfNovartis Horsham Research Centre, Horsham, UKKároly Kulich**Novartis Pharma AG, Basel, SwitzerlandDonald Banerji§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyBy Eric D Bateman, Gary T Ferguson, Neil Barnes, Nicola Gallagher, Yulia Green, Michelle Henley and Donald BanerjiArticle | Published in 2013 in European Respiratory JournalEric D Bateman*Dept of Medicine, University of Cape Town, Cape Town, South AfricaGary T Ferguson#Pulmonary Research Institute of Southeast Michigan, Livonia, Michigan, USANeil Barnes¶London Chest Hospital, Barts Health NHS Trust, London, UKNicola Gallagher+Novartis Horsham Research Centre, Horsham, UKYulia Green+Novartis Horsham Research Centre, Horsham, UKMichelle Henley+Novartis Horsham Research Centre, Horsham, UKDonald Banerji§Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.